Can I Take St. John's Wort with Ipamorelin?

Why This Combination Raises Questions

Patients using ipamorelin acetate as a growth hormone (GH) secretagogue sometimes also take St. John's Wort (Hypericum perforatum) for mood support. The concern is logical: St. John's Wort has one of the longest drug interaction profiles of any herbal supplement. The FDA has issued multiple advisories about its capacity to reduce the efficacy of prescription drugs, including oral contraceptives, cyclosporine, and certain antiretrovirals.

But not every drug is equally vulnerable to CYP3A4 induction. The question here is whether ipamorelin, a five-amino-acid synthetic peptide, actually passes through the enzymatic pathways that St. John's Wort disrupts.

How St. John's Wort Causes Drug Interactions

St. John's Wort contains hyperforin, the compound primarily responsible for its antidepressant effect and its enzyme-inducing properties. Hyperforin activates the pregnane X receptor (PXR), which upregulates expression of CYP3A4, CYP2C9, CYP1A2, and P-glycoprotein (P-gp) in the gut wall and liver [1]. A landmark pharmacokinetic study demonstrated that 14 days of St. John's Wort supplementation (300 mg three times daily) reduced the area under the curve (AUC) of the CYP3A4 probe substrate midazolam by 50% [2]. That is a clinically meaningful reduction.

The list of affected medications is long. Cyclosporine trough levels dropped by 50% in transplant patients who began St. John's Wort, leading to organ rejection in some cases [3]. Oral contraceptive breakthrough bleeding increased. Warfarin INR values fell. These are not theoretical risks.

Why Ipamorelin Is Different from Small-Molecule Drugs

Ipamorelin is a pentapeptide (molecular weight ~711 Da) that acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a). Like most injectable peptides, it is broken down by serum peptidases and tissue proteases rather than by hepatic cytochrome P450 enzymes [4]. This distinction matters. CYP3A4 induction by St. John's Wort affects small lipophilic molecules that undergo oxidative Phase I metabolism in the liver. Peptides generally bypass this pathway.

No published pharmacokinetic study has directly measured the effect of St. John's Wort on ipamorelin plasma levels. That absence of data does not prove safety, but the biochemical logic is reassuring: peptide bonds are cleaved by proteolytic enzymes, not by CYP3A4.

Pharmacokinetic vs. Pharmacodynamic Interaction Risk

When evaluating any drug-supplement combination, distinguishing between pharmacokinetic (PK) and pharmacodynamic (PD) interactions is the first step. One changes how much drug reaches its target. The other changes what happens once it gets there.

Pharmacokinetic Assessment

Ipamorelin's clearance depends on enzymatic peptide hydrolysis, renal filtration of fragments, and local tissue degradation at the injection site [4]. None of these pathways are meaningfully affected by CYP induction. P-glycoprotein, which St. John's Wort also upregulates, functions as an efflux transporter primarily for larger substrates crossing the intestinal epithelium. Because ipamorelin is injected subcutaneously rather than taken orally, intestinal P-gp induction is not relevant to its absorption.

The bottom line: a direct pharmacokinetic interaction between St. John's Wort and ipamorelin is unlikely based on current understanding of peptide metabolism.

Pharmacodynamic Considerations

The pharmacodynamic picture is less clear. St. John's Wort modulates serotonin, norepinephrine, and dopamine reuptake [5]. Dopamine tone, in particular, influences GH secretion. Dopamine agonists like cabergoline can stimulate GH release in some contexts, while serotonergic agents have variable effects on the somatotropic axis.

A 2001 study in Psychoneuroendocrinology showed that acute serotonin reuptake inhibition with citalopram increased GH release in healthy men, though the effect was modest and not sustained with chronic dosing [6]. Whether St. John's Wort's serotonergic activity could blunt or augment ipamorelin's GH-releasing effect has not been studied directly. The theoretical risk is low, but it is not zero.

The Real Risk: Co-Administered Medications

The most practical concern for patients taking both ipamorelin and St. John's Wort is not the interaction between those two agents. It is the effect of St. John's Wort on everything else in their medication regimen.

Common Medications Affected by CYP3A4 Induction

Patients on peptide therapy protocols often take other prescription medications. Statin users should know that simvastatin AUC decreased by roughly 50% when combined with St. John's Wort [7]. Patients on thyroid replacement, oral contraceptives, benzodiazepines, SSRIs, or blood thinners are all at risk for reduced drug levels.

A 2014 systematic review in the British Journal of Clinical Pharmacology cataloged 147 case reports and clinical studies of St. John's Wort drug interactions [8]. The authors concluded that patients taking any CYP3A4-metabolized drug should avoid St. John's Wort unless the combination is closely monitored. The European Medicines Agency (EMA) and the FDA's guidance on botanical drug interactions both flag St. John's Wort as a strong CYP3A4 inducer.

Building a Safe Medication Review

Before combining St. John's Wort with any peptide protocol, list every prescription and over-the-counter medication you take. Cross-check each one against a CYP3A4 substrate list. If any of your medications are CYP3A4 substrates, St. John's Wort is likely a poor choice regardless of its interaction profile with ipamorelin specifically.

Dr. Tieraona Low Dog, former member of the White House Commission on Complementary and Alternative Medicine Policy, has stated: "St. John's Wort is effective for mild depression, but it interacts with more drugs than almost any other herbal supplement. The risk-benefit calculus changes completely depending on what else the patient takes."

Dose-Separation and Practical Guidance

If a patient and their prescriber decide to continue both agents, dose separation and monitoring are reasonable precautions.

Timing Recommendations

No clinical trial has established an optimal separation window for St. John's Wort and ipamorelin. General pharmacokinetic principles suggest a minimum 4-hour separation between oral supplement dosing and subcutaneous peptide injection. Ipamorelin has a plasma half-life of approximately 2 hours, reaching peak GH release within 30 to 40 minutes of injection [4]. St. John's Wort's hyperforin component reaches peak plasma concentrations roughly 3 to 5 hours after oral dosing [9].

Administering ipamorelin at bedtime (a common protocol for GH secretagogues) and St. John's Wort in the morning provides natural temporal separation. This schedule also avoids any potential serotonergic interference at the time of peak GH pulsatility during early sleep.

What to Monitor

Patients using this combination should track several variables:

• IGF-1 levels: the most reliable surrogate marker for GH secretagogue efficacy. A baseline value before starting the combination and repeat testing at 6 to 8 weeks can reveal whether St. John's Wort is blunting the GH response.
• Mood symptoms: if St. John's Wort is being used for depression or anxiety, validated instruments like the PHQ-9 should guide dose adjustments.
• Co-prescribed drug levels: any CYP3A4 substrate medication warrants level monitoring or clinical reassessment after St. John's Wort is added or discontinued.
• Liver function: periodic hepatic panels are reasonable for patients on multiple supplements and peptides, particularly given reports of rare hepatotoxicity with high-dose Hypericum preparations [10].

What If You Are Already Taking Both?

Do not stop either agent abruptly without medical guidance. St. John's Wort discontinuation can trigger a rebound increase in CYP3A4 substrate drug levels over 1 to 2 weeks as enzyme induction fades [1]. If you suddenly stop St. John's Wort while taking a CYP3A4 substrate medication (say, a statin or a calcium channel blocker), plasma levels of that drug may temporarily spike.

Steps for Safe Reassessment

First, inform your prescribing clinician that you are taking both. Second, provide a complete supplement list. Third, request baseline IGF-1 testing if it has not been done. Fourth, discuss whether an alternative to St. John's Wort might offer mood support without the enzyme induction profile.

Alternatives with fewer CYP interactions include SAMe (S-adenosylmethionine), which has evidence for efficacy in major depression from a 2020 meta-analysis [11], and saffron extract, which showed comparable efficacy to fluoxetine 20 mg in a 2014 randomized trial (N=40) [12].

Ipamorelin's Regulatory Status and Evidence Base

Ipamorelin is not FDA-approved for any indication. It is available through 503A compounding pharmacies in the United States under the federal exemption that allows compounded medications for individual patient prescriptions. The FDA's guidance on compounded peptides outlines the regulatory framework.

Clinical Evidence for Ipamorelin

Published human data on ipamorelin is limited. A Phase II trial in post-operative ileus (N=114) demonstrated that ipamorelin 0.03 mg/kg IV accelerated return of bowel function compared to placebo [13]. Preclinical studies in animal models showed dose-dependent GH release without significant effects on cortisol or prolactin, distinguishing it from other GH secretagogues like GHRP-6 [4]. Dr. Ralf Nass, formerly of the University of Virginia Division of Endocrinology, noted: "Ipamorelin is among the most selective GHS-R1a agonists studied to date, with a favorable side-effect profile relative to older secretagogues."

The selectivity of ipamorelin for GH release without cortisol or prolactin stimulation is one reason it gained traction in the compounding pharmacy space. A 2017 review in Growth Hormone & IGF Research summarized the preclinical selectivity data [14].

St. John's Wort Evidence for Depression

By contrast, St. John's Wort has a strong clinical evidence base for mild-to-moderate depression. A Cochrane systematic review (29 trials, N=5,489) concluded that Hypericum extracts were superior to placebo and comparable to standard antidepressants for mild-to-moderate major depression, with fewer side effects than SSRIs [15]. The 2008 Cochrane review remains one of the most cited analyses in botanical medicine.

Who Should Avoid This Combination Entirely

Certain populations should not combine these agents under any circumstances. Transplant recipients on cyclosporine or tacrolimus cannot take St. John's Wort due to life-threatening drug level reductions [3]. HIV patients on protease inhibitors face the same prohibition. Patients taking warfarin, digoxin, or theophylline should avoid St. John's Wort entirely due to well-documented reductions in drug efficacy [16].

Women taking oral contraceptives should be aware that St. John's Wort reduced ethinyl estradiol AUC by 13% to 15% in controlled trials [17], enough to risk contraceptive failure.

For patients without these contraindications who want to combine St. John's Wort with ipamorelin, the direct interaction risk appears low. The indirect risk depends entirely on what else is in the medication regimen.